At close: December 20 at 4:00:02 PM EST
Breakdown
TTM
10/31/2023
10/31/2022
10/31/2021
10/31/2020
Operating Cash Flow
-8,377.0000
-6,209.0000
-6,492.0000
-4,938.0000
-6,175.6710
Investing Cash Flow
2,816.0000
-5,602.0000
-10,728.0000
-3,917.0000
-305.7910
Financing Cash Flow
3,588.0000
366.0000
452.0000
31,566.0000
9,406.8980
End Cash Position
1,225.0000
915.0000
12,360.0000
29,128.0000
6,417.0610
Capital Expenditure
--
--
--
--
-15.7910
Issuance of Capital Stock
--
--
--
31,126.0000
9,266.1770
Free Cash Flow
-8,377.0000
-6,209.0000
-6,492.0000
-4,938.0000
-6,191.4620
10/31/2020 - 10/7/1983
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
INMB INmune Bio, Inc.
4.4000
-0.45%
COYA Coya Therapeutics, Inc.
5.24
+1.55%
GANX Gain Therapeutics, Inc.
1.5600
-0.64%
RCKTW Rocket Pharmaceuticals, Inc.
0.0252
-3.82%
LTRN Lantern Pharma Inc.
3.1450
-2.02%
VNDA Vanda Pharmaceuticals Inc.
4.7800
+3.24%
DMAC DiaMedica Therapeutics Inc.
6.41
+31.62%
CEROW CERo Therapeutics Holdings, Inc.
0.0090
-14.29%
FHTX Foghorn Therapeutics Inc.
5.14
+3.21%
BRTX BioRestorative Therapies, Inc.
1.5500
+6.90%